hepatocellular cancer
Conditions
Interventions
Research group:Within 2 weeks before treatment, laboratory tests, 99mTc MMA hepatic artery angiography (using cone beam CT imaging), and hepatopulmonary shunt assessment (99mTc MAA, SPECT/CT) were con
Sponsors
Fujian Medical University Cancer Hospital, Fujian Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Diagnosed as primary liver cancer that cannot be surgically removed or undergo radical ablation, with liver tumors as the main cause; (2) Age = 18 years old; (3) Physical condition score ECOG = 2; (4) Expected survival period exceeds 3 months; (5) Meet the hematological indicators for treatment: hemoglobin = 90g/L, absolute neutrophil count>1500/mm ³ Platelet count = 80 × 10 °/L, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST)<5 times upper normal limit (ULN), total bilirubin<3 × ULN, blood creatinine<1.5 × ULN, prothrombin time (PT) or international standardized ratio (INR), activated partial thromboplastin time (APTT)<1.5 × ULN; (6) Suitable for selective arterial catheterization and angiography; (7) The maximum diameter of the tumor is greater than 8cm, or 90Y-SIRT treatment is planned, but the LSF detected by 99mTc MMA hepatic angiography is greater than 20%, or a single lung radiation dose is expected to exceed 30Gy.
Exclusion criteria
Exclusion criteria: (1) Severe liver dysfunction, including severe jaundice, hepatic encephalopathy, refractory ascites, or hepatorenal syndrome, with a Child Pugh grade of C; (2) Incorrectable coagulation dysfunction; (3) Renal dysfunction, creatinine>176.8 µ Mol/L or creatinine clearance rate2 points, cachexia or multiple organ failure; (7) Abnormal anatomical structure of hepatic artery blood vessels, or severe uncorrectable hepatic artery portal vein fistula or hepatic artery hepatic vein shunt; (8) Cancer thrombus and embolism in the main portal vein, with less formation of collateral vessels, and inability to perform portal vein stent recanalization to restore hepatic blood flow to the main portal vein; (9) Uncorrectable hepatic gastrointestinal artery shunt; (10) Severe iodine contrast agent allergy; (11) Individuals who have used bevacizumab within 4 weeks prior to treatment; (12) Other: including pregnant or lactating women, etc
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate;lung shunt fraction; | — |
Countries
China
Contacts
Public ContactJing Feng Liu
Fujian Medical University Cancer Hospital, Fujian Cancer Hospital
Outcome results
None listed